A Clinical Trial Using Atezolizumab
Alveolar soft part sarcoma (ASPS) is a rare, slow growing cancer that often occurs in adolescents and young adults. It can be difficult to treat with surgery, chemotherapy or radiation. Researchers at the National Institutes of Health (NIH) are enrolling participants, 6 years and older, in a new research study to test if an immunotherapy study drug called atezolizumab can shrink the cancer. The study is for people where standard treatment has not worked or is not an option.
In some types of cancer, atezolizumab allows the body’s immune cells to recognize and attack tumor cells. In the study, atezolizumab is given as a 1-hour infusion in an outpatient setting every 21 days. All participants will receive atezolizumab – there is no placebo.
Participants will receive study treatment at no charge. Travel within the United States may be reimbursed.
The NIH Clinical Center, America's Research Hospital is located in Bethesda, Maryland (in the Washington, DC metro area).
For more information:
NIH Clinical Center Office of Patient Recruitment
1-800-411-1222 (refer to 17-C-0074)
TTY for the deaf or hard of hearing: 1-866-411-1010
Se habla español
Or go online:
Refer to study #17-C-0074
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)